Model Integration and Configuration for Bioequivalence

Data Characteristics

Bioequivalence (BE) study data primarily includes pharmaceutical research, bioanalytical method validation, clinical trial protocols, statistical analysis reports, and the final bioequivalence evaluation report. Data sources are diverse, encompassing literature databases, raw laboratory data (e.g., chromatograms, mass spectra), and clinical research organization case report forms (CRFs). Data update frequency is relatively low, occurring mainly at key milestones such as project initiation, protocol amendments, data lock, and report writing. Document structures are highly standardized, adhering to ICH guidelines and regulatory submission requirements from various national drug agencies, such as China's NMPA CDE requirements. Reports contain both extensive structured data (e.g., Area Under the Curve AUC, Peak Concentration Cmax, Time to Peak Concentration Tmax) and unstructured text (e.g., trial protocol descriptions, method validation details, safety evaluations). Fields and units are strictly consistent; for example, drug concentrations are typically expressed in ng/mL or µg/mL, time in h or min, and statistical parameters like geometric mean ratio confidence intervals are usually expressed as percentages.

Constraints on Model Integration and Configuration

The standardized structure and strict definition of key parameters in bioequivalence data require models to have robust structured information extraction capabilities and accurately identify specific fields and units. Low update frequency implies higher initial costs for model training and knowledge base construction, but lower subsequent maintenance. Models should focus on long-term knowledge retention and minimal incremental updates. The mix of structured and unstructured data in documents challenges model information extraction and knowledge representation, necessitating the ability to process tables, charts, and natural language text simultaneously. For example, extracting key exclusion/inclusion criteria from clinical trial protocols and comparing them with actual data in statistical analysis reports. Strict requirements for specific fields and units constrain the model to generate highly accurate and consistent content, avoiding unit confusion or data format errors. This requires the model to have strict validation mechanisms. Additionally, due to the specialized nature of the data, the indexing model must accurately match specialized terminology in the biomedical field to ensure recall relevance.

Configuration Settings

Configuration Item	Recommended Value	Rationale
`maxContext`	`8000 tokens`	Bioequivalence reports are often long, requiring a larger context window to understand complete logic and related data.
`Chunk size` (Segment Length)	`500–800 characters` (characters)	Balances semantic completeness and indexing efficiency, preventing dilution by irrelevant information in overly long segments and loss of context in overly short segments.
`Recall count` (Recall Count)	`Top 8–12 entries` (top 8–12 items)	The specialized nature of bioequivalence data demands high accuracy; increasing recall count improves key information coverage.
`Similarity threshold` (Similarity Threshold)	`0.75`	Ensures precision of recalled content, filtering out irrelevant general biomedical knowledge.
`Rerank result count` (Rerank Return Count)	`Top 5 entries` (top 5 items)	Refines sorting based on a high recall count, presenting the most relevant few pieces of information to the user.
`PARSE_FILE_TIMEOUT_SECONDS`	`600 seconds` (seconds)	Bioequivalence reports may contain numerous charts and complex structures, requiring extended parsing time.

Common Pitfalls

Symptom: The model frequently omits or incorrectly cites key statistical parameters (e.g., confidence intervals for AUC, Cmax) when generating regulatory submission summaries. Reason: The model fails to effectively distinguish between unstructured descriptions and numerical values in structured tables when processing mixed data types, leading to incomplete or inaccurate information extraction.
Symptom: In the workflow's classify module, the expected AI model cannot be selected for classification. Reason: The deployed AI model is not correctly registered or configured in FastGPT's model_config.json file, preventing the interface from loading the list of available models.
Symptom: During tool calls, the content generated by the model does not strictly adhere to the specific format and unit requirements of bioequivalence reports. Reason: The model was not sufficiently trained or fine-tuned on the specific output specifications for bioequivalence reports, or it lacks strict validation mechanisms for units and formats.

Verification Steps

Select a typical bioequivalence study report. Build and index a knowledge base using FastGPT. Check the segment content in the Knowledge Base Management interface for completeness, accuracy, and inclusion of key statistical indicators.
Test with query statements containing core bioequivalence concepts and parameters, such as "Summarize the bioequivalence evaluation results for [Drug Name]". Verify that the model's returned Recalled Content precisely matches relevant paragraphs in the report.
Simulate a regulatory submission document drafting scenario. Request the model to generate bioequivalence conclusions for a specific drug based on the knowledge base content. Check that the values and units for parameters like AUC and Cmax in the output text are correct and that the format meets expectations.

The values provided are common starting points and should be measured against the reader's own samples.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.